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OBJECTIVE—The QUASAR (Quality Assessment Score and Cardiovascular Outcomes in
Italian Diabetes Patients) study aimed to assess whether a quality-of-care summary score pre-
dicted the development of cardiovascular (CV) events in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS—In 67 diabetes clinics, data on randomly se-
lected patients were extracted from electronic medical records. The score was calculated using
process and outcome indicators based on monitoring, targets, and treatment of A1C, blood
pressure, LDL cholesterol, and microalbuminuria. The score ranged from 0 to 40.
RESULTS—Overall, 5,181 patients were analyzed; 477 (9.2%) patients developed a CV event
afteramedianfollow-upof28months.Theincidencerate(per1,000person-years)ofCVeventswas
62.4inpatientswithascoreof,15,41.0inthosewithascorebetween20and25and36.7inthose
withascoreof.25.Multilevelanalysis,adjustedforclusteringandcase-mix,showedthattheriskto
developanewCVeventwas84%higherinpatientswithascoreof,15(incidencerateratio[IRR]=
1.84;95%conﬁdenceinterval[CI]1.29–2.62)and17%higherinthosewithascorebetween15and
25 (IRR = 1.17; 95% CI 0.93–1.49) compared with those with a score of .25. Mean quality score
varied across centers from 16.5 6 7.5 to 29.1 6 6.3. When the score was tested as the dependent
variable,itemergedthat18%ofthevarianceinthescorecouldbeattributedtosettingcharacteristics.
CONCLUSIONS—Our study documented a close relationship between quality of diabetes
careandlong-termoutcomes.Asimplescorecanbeusedtomonitorqualityofcareandcompare
the performance of different centers/physicians.
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T
hegrowingburdenoftype2diabetes
mellitus and its cardiovascular com-
plications(1–2)hasforcedAmerican
and European organizations to work for
the development, speciﬁcation, andﬁeld-
testing of measures for quality of diabetes
care (3–9).
Qualitymeasuresincludeprocessand
intermediateoutcomeindicators,selected
undertheassumptionthattheyarelinked
to downstream health outcomes. Process
measures denote what is actually done
tothepatient(i.e.,whetherA1C[HbA1c]
has been measured or an ACE inhibitor
prescribed in the presence of a speciﬁc
indication).Outcomemeasuresarethere-
sults of a patient health status as a conse-
quence of the care delivered. Intermediate
outcomes include laboratory measure-
ments, physical signs, or symptoms.
Although widely used by many or-
ganizations worldwide, it is unclear
whether selected indicators, which usu-
ally include process and intermediate
outcome measures, truly reﬂect the qual-
ity of care delivered and its long-term
consequences (10). Outcome measures
have been criticized because they can be
affected by factors other than the quality
of care,such as patient characteristicsand
attitudes (11). However, process mea-
sures alone do not fully describe the
wholeprocessofcare.Asanexample,reg-
ular testing of HbA1c levels does not en-
sure that the physician will adequately
treat persistently elevated values (12).
Furthermore, positive results in the short
run could fail to be sustained in the long
run, even in the presence of scientiﬁcally
validated indicators. In fact, although
widely used, it is unclear to what extent
process and intermediate outcome mea-
sures are able to predict long-term effects
on patients’ health. The Associazione
Medici Diabetologi (AMD), an Italian di-
abetes scientiﬁc society, developed qual-
ity indicators to be used for the routine
monitoringofdiabetescare(9,13).Inpar-
allel, AMD launched the QUASAR (Qual-
ity Assessment Score and Cardiovascular
Outcomes in Italian Diabetes Patients)
studytoevaluatewhethertheseindicators
were able to predict the incidence of ﬁnal
outcomes. In particular, we assessed
whether a quality-of-care summary score
estimated at baseline from the combina-
tion of the main process and intermediate
outcome indicators predicted the devel-
opment of cardiovascular (CV) events
during 30 months.
RESEARCH DESIGN AND
METHODS
The Italian health care system
All Italian citizens are covered by a govern-
ment health insurance and are registered
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ORIGINAL ARTICLEwith a general practitioner (GP). Primary
care for diabetes is provided by GPs and
diabetesoutpatientclinics(DOCs).Patients
can choose one of these two ways of
accessing the health care system or they
can be referred to DOCs by their GPs.
Within the Italian health care system more
than 600 DOCs are in operation.
Study design
This observational longitudinal study
involved DOCs adopting an electronic
medical record system for the routine
management of outpatients.
Each center was asked to enroll up to
100 patients, selected among individuals
havingascheduledvisitduring6months,
using random sampling lists. Eligible in-
dividuals were men and women patients
with type 2 diabetes mellitus, aged $18
years, irrespective of diabetes treatment
and duration. Newly diagnosed patients
were not included. At baseline, clinical
data were automatically extracted from
electronic clinical records using an ad
hoc software. Information on CV events
that occurred during three years was col-
lected on ad hoc case report forms
(Supplementary Fig. A1). All the data
wereanalyzedanonymously,andpatients
were identiﬁed only by a numeric code.
Patients were enrolled between Jan-
uary 2006 and November 2007 and
f o l l o w e du pu n t i lS e p t e m b e r2 0 0 9 .T h e
study was approved by local ethics com-
mittees of all participating centers.
Quality-of-care summary score
A quality-of-care summary score (Table 1),
developed and validated in a previous
study (14), was applied to the QUASAR
population to conﬁrm its ability to predict
the incidence of major vascular events.
The score includes those process and
intermediate indicators for which a clear
link with vascular complications was
demonstrated and effective preventive
strategies are available.
For each item, the highest score was
assigned when the desired goals was
attained, whereas the lowest score was as-
signed when the patient was not treated
for the speciﬁc condition despite elevated
values or when the patient showed un-
satisfactory values despite the treatment.
Monitoring HbA1c,b l o o dp r e s s u r e ,l i p -
ids, or microalbuminuria less frequently
than once a year was attributed an inter-
mediate scoring under the assumption
that these parameters could be less fre-
quently monitored in individuals with
less severe diabetes and in better control.
After having developed the score in the
QuED (Quality of Care and Outcomes
in Type 2 Diabetes) study, we have em-
piricallytestedthisaspectintheQUASAR
study,wherewehavealsocollectedblood
samples, which were centrally analyzed.
From these data it emerged that patients
monitored less frequently tended to have
lower HbA1c and lipid levels and were
markedly less likely to have microalbu-
minuria.
Toavoidastrictdependencefromthe
data, the scores attributed to each process
and outcome measure were decided a
priori and not based on weights derived
from regression models applied to the
data. Overall, the quality score ranges
between 0 and 40, with a higher score
reﬂecting better quality of care. The scor-
ing system was applied to the data col-
lected at study entry and tested as a
predictor of incident CV events. Indica-
tors were calculated using the last in-
formation relative to the 12 months
preceding the recruitment. Because nor-
mal ranges for glycated hemoglobin
varied among different centers, the per-
cent change with respect to the upper
normal value (actual value/upper nor-
mal limit) was estimated and multiplied
by 6.0.
LDL cholesterol was estimated by the
Friedwald equation. The score only in-
cluded those indicators that could be
easily retrieved from medical records.
Additional indicators, such as foot or
eye examination, although representing
key components of diabetes care, were
not considered, since information was
reported in nonstandardized format in
medical records.
Incident CV events
Information on CV events that occurred
over three years was collected. The pri-
mary composite end point was repre-
sented by total CV events, including
angina, myocardial infarction (MI), stroke,
transient ischemic attack, coronary revas-
cularizationprocedures,lower-limb com-
plications (claudication, ulcer, gangrene,
amputation, aortic-femoral revasculariza-
tion procedures), and CV mortality.
Secondary end points were repre-
sented by major CV events (nonfatal
M I ,n o n f a t a ls t r o k e ,C Vm o r t a l i t y ) ,M I ,
cardiac revascularization procedures,
stroke, lower-limb complications, CV
deaths, and total deaths.
MIwasdeﬁnedbasedonthepresence
of at least two of the following: 1)t y p i c a l
ischemic chest pain, pulmonary edema,
syncope, or shock; 2) development of
pathological Q-waves and/or appearance
or disappearance of localized ST-eleva-
tion followed by T-wave inversion in
two or more of twelve standard electro-
cardiograph leads; and 3)i n c r e a s ei nt h e
concentration of serum enzymes consis-
tent with MI.
Stroke was deﬁned on the basis of the
presence of unequivocal signs or symp-
toms of focal or global neurologic deﬁcit,
with sudden onset, lasting more than
24 h, and considered of vascular origin.
The following criteria were adopted
to deﬁne CV death: death occurring
within 28 days after the onset of the
documented diagnosis of MI or stroke,
in the absence of any other evident cause;
sudden deaths; deaths from heart failure;
and all other deaths classiﬁed as cardio-
vascular (International Classiﬁcation of
Disease, ninth edition, Clinical Modiﬁca-
tion). The absence of any evident non-
cardiovascular cause was sufﬁcient to
deﬁne a death as cardiovascular.
All of the events were certiﬁed by the
participatingcliniciansandwerebasedon
clinical documentation. Patients were
contacted by phone if their last visit to
the center had occurred more than 6
months before.
Statistical analysis
Basedontheresultsofthepreviousstudy,
the quality score was categorized in three
Table 1—Quality-of-care scoring system
Quality-of-care indicator Scoring
HbA1c
Measurement ,1/year 5
$8.0% 0
,8.0% 10
Blood pressure
Measurement ,1/year 5
Values $140/90 mmHg,
irrespective of treatment 0
Values ,140/90 mmHg 10
Lipid proﬁle measurement ,1/year 5
LDL cholesterol, mmol/L (130 mg/dL)
$3.37, irrespective of treatment 0
,3.37 10
MA measurement ,1/year 5
Not treated with ACE inhibitors/ARBs
despite the presence of MA 0
Treated with ACE inhibitors/ARBs in
the presence of MA or MA absent 10
Score range 0–40
MA, microalbuminuria; ARBs, angiotensin receptor
blockers.
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Quality of diabetes care and CV eventsclasses; however, because of a general
trend of improvements in the average
quality of care in the last years, the cutoffs
of the middle class were shifted ahead by
5p o i n t s( ,15, 15–25, .25). Patients’
characteristics according to score classes
were compared using the x
2 test for cate-
gorical variables and the Kruskal-Wallis
one-way ANOVA for continuous vari-
ables.
Incidence rates (IR) by score classes
were expressed in terms of events per
1,000 person-years.
ProbabilitiesofCVeventaccordingto
score classes were calculated using the
Kaplan-Meier method and compared us-
ingthelog-ranktest.AllreportedPvalues
are two-sided.
To account for the multilevel nature
of the data (patients clustered within
diabetes clinic), and to control simulta-
neously for the possible confounding
effects of the different covariates, we
used multilevel Poisson regression mod-
els to investigate whether the score was
an independent predictor of CV events
incidence (15). In multilevel analyses
patient-related characteristics were tested
as level 1 variables, whereas setting-
related characteristics represented level 2
variables. The following patients’ charac-
teristics were tested: age, sex, BMI, dura-
tion of diabetes and treatment, smoking,
and historyofprevious CV event. Therisk
ofCVeventsaccordingtothescoreclasses
was expressed in terms of incidence rate
ratio (IRR) and 95% conﬁdence inter-
vals (95% CIs), with a score of .25 as
the reference category.
Finally, we estimated the intraclass
correlation coefﬁcient (ICC) using the
score as dependent variable to evalu-
ate the extent to which the score varies
between centers as compared with
within-center variation, taking patient
case-mix into account (16). The higher
the ICC, the greater the inﬂuence of the
physician-level on the quality-of-care
score.
RESULTS—The study was conducted
in 67 diabetes clinics, and 5,181 patients
were enrolled and followed up for a me-
dian of 28 months (interquartile range
24–3 1 ) .O v e r a l l ,6 . 7 %o ft h ep a t i e n t s
had a score of ,15, 68.2% had a score
between 15 and 25, and 25.1% had a
score of .25. Patients’ characteristics ac-
cording to the score classes are reported
in Table 2. Patients with the lowest score
had a longer diabetes duration, and a
larger percentage of them were already
treated with insulin as compared with pa-
tients in the other two score classes.
During the follow-up, 477 (9.2%)
patients developed one or more CV
events. The CV event rate was strictly
related to the score, being of 62.1 per
1,000 person-years in patients with a
score of ,15, 41.0 per 1,000 person-
years in those with a score between 15
and 25, and 36.7 per 1,000 person-years
in those with a score of .25. Unadjusted
Kaplan-Meier curves show that a score of
,1 5w a sa s s o c i a t e dw i t has i g n i ﬁcant
higher likelihood to develop a CV event
(Fig. 1).
Multilevel analysis, adjusted for clus-
tering,age,sex,BMI,durationofdiabetes,
smoking, and history of CV event,
showed that the risk to develop a new
CV event was 84% greater in patients
with a score of ,15 (IRR = 1.84; 95% CI
1.29–2.62) and 17% higher in those
with a score between 15 and 25 (IRR =
1.17; 95% CI 0.93–1.49), as compared
with those with a score of .25. A trend
of increasing overall mortality according
to the qualityscorewasalso documented,
although statistical signiﬁcance was not
reached (IRR = 1.68; 95% CI 0.78–3.63
and IRR = 1.35; 95% CI 0.83–2.21 for a
score of ,15 and between 20 and 25, re-
spectively, compared with a score of
.25). The same trend of association
was found for most of the outcomes,
although statistical signiﬁcance was
reached for lower limb complications
only (Fig. 2). The strong correlation be-
tween the score of quality of care and CV
events was evident in patients without
previous CV events as well as in those
who had already experienced a previous
event (Supplementary Table A1).
Finally, the mean quality score varied
substantially across centers (from 16.5 6
7.5 to 29.1 6 6.3). Mean quality score by
center, adjustedforpatient characteristics
and clustering effect, is in Supplementary
Fig. A2. When the score was tested as the
dependent variable, it emerged that 25%
of the variance in the score (ICC = 0.25)
couldbeattributedtobetweencentervar-
iation (i.e., to setting characteristics).
When adjusting for case-mix (age, sex,
BMI, duration of diabetes, previous CV
events), variance attributable to center-
level characteristics remained elevated
(ICC = 0.18).
CONCLUSIONS—Improving health
outcomesistheultimategoalofthehealth
Table 2—Patient characteristics according to quality-of-care score
Characteristic
Quality-of-care score
P* ,15 15–25 .25
N (%) 345 (6.6) 3,531 (68.2) 1,305 (25.2)
Sex (% men) 51.6 57.8 61.8 0.001
Age (years) 64.7 6 8.9 64.9 6 9.2 63.0 6 9.6 ,0.0001
BMI (kg/m
2) 30.7 6 5.2 29.9 6 5.0 29.2 6 4.8 ,0.0001
Smoking ,0.0001
No 66.5 61.8 51.6
Ex 16.3 16.9 21.2
Yes 17.3 21.3 27.3
Diabetes duration (years) 11.9 6 8.5 10.2 6 8.7 9.1 6 8.0 ,0.0001
Treatment ,0.0001
Diet alone 0.7 7.7 10.2
Oral agents 60.6 68.5 72.0
Insulin 6 oral agents 38.7 23.8 17.8
Previous CV event 20.0 18.9 21.3 0.18
HbA1c (%) 9.1 6 1.3 7.5 6 1.4 6.8 6 1.0 ,0.0001
Blood pressure (mmHg)
Systolic 152.2 6 15.4 144.9 6 17.0 128.1 6 13.6 ,0.0001
Diastolic 85.6 6 9.4 82.6 6 9.2 77.3 6 7.5 ,0.0001
Cholesterol (mg/dL)
Total 224.3 6 41.2 193.5 6 39.9 177.3 ,0.0001
LDL 152.3 6 28.1 115.0 6 35.0 100.2 6 25.2 ,0.0001
HDL 50.8 6 11.6 51.6 6 13.2 50.4 6 13.3 0.03
Triglycerides (mg/dL) 174.9 6 107.5 146.6 6 126.73 138.1 6 82.8 ,0.0001
Dataarepercentagesormean6SD.*Pvaluesrefertox
2forcategoricalvariablesandKruskal-Wallisone-way
ANOVA for continuous variable.
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Rossi and Associatescare system and should represent the
main aim for any quality measurement
program. From the data on more than
5,000 patients with type 2 diabetes mel-
litusroutinelycaredforbydiabetesclinics
a n df o l l o w e du pf o ram e d i a no f2 8
months, we conﬁrmed that a quality-of-
care summary score, based on a restricted
number of indicators, is able to predict
total cardiovascular events. The trend of
increase in the event rates with the pro-
gressive reduction of the score is clear for
all the selected outcomes, including over-
all mortality, although statistical signiﬁ-
cance was not reached.
Our study substantially reproduces
the body of evidence emerged by the
QuED study (14), conﬁrming the valid-
ity and applicability of the instrument.
In comparison with previous studies
(14,17), conducted ten years ago in
comparable settings, quality of care has
improved, as reﬂected by the lower per-
centageofpatientsscoringbelow15and
the general shift of the score distribution
toward higher values. Patients with a par-
ticularly high risk of negative outcomes,
i.e., those with a score of ,15, now
represent a small minority (6.7%). Acting
to improve the performance in this small
subgroup would hardly translate into tan-
gible results at the population level, al-
though individual patients would beneﬁt
f r o ma n yq u a l i t yi m p r o v e m e n t .O nt h e
other side, a large proportion of patients
(i.e., 68.2%) lies in the 15–25 score
range, associated with a nearly 20% in-
creased risk of major events. A sub-
stantially greater beneﬁtc o u l dt h u sb e
expected by improving the monitoring
and treatment of major cardiovascular
risk factors in such a large population.
The score can help identifying patients
whose quality of care is suboptimal and
in which aspects of care need to be im-
proved.
Reducing variation in health care de-
livery represents a key component of any
quality improvement initiative (18). In
our study, mean quality score widely dif-
fered among centers. It has been argued
that process and intermediate outcomes
can be affected not only by medical inter-
ventions but also by patient factors (19);
inother words,thescoremight reﬂectpa-
tient variation rather than disparities in
the quality of care. We showed that a rel-
evant proportion of total variance was ex-
plained by center-level characteristics
(16), even after adjusting for patient
case-mix. To this respect, the score seems
to efﬁciently capture differences in the
performance of the centers. The wide var-
iationinhealthcaredeliverystronglysug-
gests that a substantial proportion of
cardiovascular events could be avoided
byprovidinghigher qualityand more ho-
mogeneouslevelsofcare.Theuseofmore
standardized approaches could lead to
sizeable savings in care and outcomes,
particularly focusing the attention on the
large proportion of patients falling in the
intermediate category of the score.
The possibility of calculating the
quality score from electronic medical re-
cords in an easy and quick way makes its
use particularly appealing. By allowing its
automatic calculation, the score could be
used not only to identify patients at risk
for poor quality of care but also to
monitor the performance of the center
across the years. The score can also be
used for multicenter, continuous quality
improvement initiatives by providing a
benchmark to which to compare individ-
ual performance. This approach is being
adopted in the context of a wide national
initiative in Italy, involving over 250 di-
abetes clinics for a total of half a million
patients. The score will be calculated at
the national, regional, and individual
centerlevels, andthe overallperformance
will be measured against that of the best
performers.
Some of the potential limitations of
our study need to be discussed. First,
physicians were selected according to
their willingness to participate. They
could thus represent those clinicians
more interested in diabetes care and
therefore not reﬂect the diabetes care
delivered by Italian physicians. It is thus
Figure 1—Event-free survival; all patients by group score.
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Quality of diabetes care and CV eventspossible that the differences documented
in our study are underestimated and that
the true variability in process and out-
come measures is even greater. Similarly,
patients attending diabetes clinics might
differ from those primarily cared for by
GPs; therefore, they could not be repre-
sentative of all patients with diabetes.
Second, the attainment of the desired
therapeutic goals could be at least par-
tially dependent on unmeasured patient
factors; therefore, the intermediate out-
come measures considered might not
fully reﬂect the care provided. Third, the
relatively short follow-up did not allow a
robust estimate of the impact of the score
on individual cardiovascular outcomes.
Nevertheless, our results are highly con-
sistent with those of the QuED study.
Furthermore, an update of the study has
been scheduled to evaluate the incidence
rate of CV events after a 5-year follow-up.
Finally, we have developed a score able to
predict major cardiovascular events; a
comprehensive quality-of-care measure
should obviously also include process
and outcome measures related to micro-
vascular complications.
In conclusion, our study doc-
umented a close relationship between
quality of diabetes care and long-term
outcomes. Our ﬁndings support the use
of the indicators identiﬁed as an im-
portant tool to assess the level of care
provided within systems of care to pop-
ulations of patients with diabetes.
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